Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants must be H. pylori-positive patients at baseline (Visit 1)~2. Participants must be endoscopically confirmed to have scarred gastric ulcer or duodenal ulcer at baseline (Visit 1).~   However, if a history of ulcers is confirmed by the medical interview or previous medical record, Participants whose gastric ulcer scar or duodenal ulcer scar has disappeared may be included in the study.~3. Outpatient (including inpatient for examination)~Exclusion Criteria:~1. Participants who have received H.pylori eradication treatment~2. Participants who have either acute upper gastrointestinal bleeding, gastric ulcer \[mucosal defect (with white coating including clot adherence) of 3 mm or larger in size\], duodenal ulcer \[mucosal defect (with white coating including clot adherence) of 3 mm or larger in size\], acute gastric mucosal lesion (AGML), or acute duodenal mucosal lesion (ADML) on endoscopic examination at baseline (Visit 1).~   However, participants with gastric erosion or duodenal erosion may be included in the study.~3. Participants who have received or who are scheduled to undergo surgery which affects gastric acid secretion (ex, resection of upper gastrointestinal tract, vagotomy, etc)~4. Participants who cannot be treated with medicinal treatment (ex, perforation, pyloric stenosis or large hemorrhage, etc)~5. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders~6. Participants with hepatic or renal impairment receiving treatment with colchicines~7. Participants who have a history of hypersensitivity or allergy to TAK-438 (including its excipients), PPIs, penicillin antibiotics, macrolide antibiotics, or antitrichomonal agents~8. Participants with infectious mononucleosis~9. Participants with an organic disease of the brain or spinal cord

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAK-438 20 mg BID (Type: EXPERIMENTAL): TAK-438 20 mg, tablets, orally, twice daily for 1 week~Lansoprazole placebo-matching capsules, orally, twice daily for 1 week~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week
- Lansoprazole 30 mg BID (Type: EXPERIMENTAL): TAK-438 placebo-matching tablets, orally, twice daily for 1 week~Lansoprazole 30 mg, capsules, orally, twice daily for 1 week~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week

Based on this trial design, predict the completion outcome and termination type (if applicable).